Study analysis · Cardiovascular Diabetology · 2023
Your next heart attack might be predicted by a blood test you already had — and it costs nothing.
People with higher numbers on two simple blood tests had up to 29% more heart disease over 8 years, even if they felt fine.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study looked at a bunch of people over many years and found that those with higher TyG and TG/HDL numbers tended to get heart problems later. But it didn’t make anyone change their habits — it just watched what happened. So we can say these numbers are linked to heart disease, but we can’t say they cause it.
What’s the bottom line?
Scientists checked two easy-to-calculate numbers from blood tests to see if they could guess who might get heart disease later.
How strong is this study?
This study is super well-done because it followed almost half a million people for over 8 years and checked lots of things like age, smoking, and blood pressure to make sure the results weren’t just random. But since it didn’t change anyone’s behavior, we still can’t be 100% sure the numbers themselves are the cause — just strong clues.
75 / 100
- COI disclosure+40/40
- Data availability+35/35
- Code availabilitycode not shared
56 / 100
- Randomizationnot randomized
- Blindingblinding unclear
- Control group+15/15
- Sample size (n=403335)+20/20
- Follow-up+10/10
100 / 100
77 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 572 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. This is an observational cohort study with no randomization or intervention; it can identify associations but cannot rule out confounding factors or establish direct cause-effect relationships.
No Conflicts
No conflicts of interest identified
No conflicts of interest or funding statements were disclosed in the study text. The analysis used publicly available UK Biobank data with no indication of industry involvement or author financial ties.
Independent Analysis Safeguards
- Analysis conducted using UK Biobank's standardized protocols
- Statistical analysis performed with SAS software using publicly available methods
- Multiple imputation for missing data
- Adjustment for multiple confounders in models
- Sensitivity analyses excluding early CVD cases
The study relies entirely on the UK Biobank dataset, which is a publicly funded, open-access resource. No author affiliations, funding sources, or conflict of interest declarations are provided in the text. While this absence prevents confirmation of COI disclosure, the use of a large, independent, population-based cohort with standardized data collection minimizes potential bias.
Key takeaways
- 01
People with higher numbers had up to 29% more heart disease over 8 years.
- 02
These numbers were linked to diabetes, high blood pressure, and bad cholesterol, which explained most of the risk.
- 03
Yes — even if someone doesn’t have diabetes or high blood pressure yet, these simple blood markers can signal higher heart disease risk years before symptoms appear.
Surprising findings
- Non-fasting blood samples were used — and the results still held up.Doctors usually require fasting for lipid and glucose tests because levels fluctuate after eating — yet these ratios predicted heart disease just as well without fasting.
- The TG/HDL-C ratio was a stronger predictor of coronary heart disease than the TyG index.Many assumed TyG index (which includes glucose) would be more powerful since diabetes is a major risk factor — but the simple triglyceride-to-HDL ratio outperformed it, with a 37% higher CHD risk in the top quartile.
Practical takeaways
Ask your doctor to calculate your TG/HDL-C ratio from your last lipid panel — if it’s above 3.0, consider lifestyle changes to lower triglycerides and raise HDL.
This study was done on middle-aged UK Biobank participants — results may not apply to younger people, non-Europeans, or those with existing diabetes.
high confidenceIf you have prediabetes or metabolic syndrome, track your TyG index over time — even small increases may signal rising heart risk.
Single baseline measurements can’t capture changes — you need repeated tests to see trends.
medium confidenceWhy this study matters
The 2-Number Heart Risk Test
The study found that two easy-to-calculate ratios — the TyG index (log of triglycerides × glucose) and TG/HDL-C ratio (triglycerides divided by HDL cholesterol) — predicted heart disease risk. Each 1-SD increase in TG/HDL-C ratio raised risk by 12%, and those in the top quartile had 29% higher risk than those in the bottom.
You don’t need expensive scans or genetic tests — your last routine blood work might already hold the key to your future heart health.
Why It’s Not Just About Cholesterol
Dyslipidemia, type 2 diabetes, and hypertension together explained 56% of the TyG index’s link to heart disease and 47% of the TG/HDL-C ratio’s link — meaning insulin resistance drives heart disease mostly by triggering these three conditions.
This flips the script: it’s not just 'bad cholesterol' causing heart attacks — it’s insulin resistance quietly setting off a chain reaction of metabolic problems.
It Predicts Heart Disease — But Not Stroke
Despite strong links to coronary heart disease (CHD), neither biomarker showed a statistically significant association with stroke after adjusting for confounders — suggesting they’re more specific to atherosclerosis in heart arteries.
Most people think 'heart disease' means all cardiovascular events — but this study shows these markers are surprisingly selective, which could change how we screen patients.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Scientists checked two easy-to-calculate numbers from blood tests to see if they could guess who might get heart disease later.
Research results
People with higher numbers had up to 29% more heart disease over 8 years. These numbers were linked to diabetes, high blood pressure, and bad cholesterol, which explained most of the risk.
What this means - more context
Yes — even if someone doesn’t have diabetes or high blood pressure yet, these simple blood markers can signal higher heart disease risk years before symptoms appear.
This study investigates whether the triglyceride-glucose (TyG) index and triglyceride-to-HDL cholesterol (TG/HDL-C) ratio, surrogate markers of insulin resistance, predict cardiovascular disease (CVD) risk in a European population.
In a prospective cohort of 403,335 middle-aged UK Biobank participants followed for 8.1 years, both TyG index and TG/HDL-C ratio were independently associated with increased risk of total CVD and coronary heart disease (CHD), but not stroke, after adjusting for traditional risk factors. The associations were largely mediated by dyslipidemia, type 2 diabetes, and hypertension.
Methods Used
Prospective cohort study using Cox proportional hazards models to analyze incident CVD in 403,335 adults free of CVD at baseline. Biomarkers (TyG index and TG/HDL-C ratio) were calculated from non-fasting blood samples. Mediation analyses assessed contributions of dyslipidemia, type 2 diabetes, and hypertension. Adjustments included age, sex, smoking, BMI, blood pressure, cholesterol, diabetes, and medication use.
Main Finding
Each 1-SD increase in log-transformed TyG index and TG/HDL-C ratio was associated with 8% and 12% higher CVD risk, respectively. Highest vs. lowest quartiles showed 19% and 29% higher CVD risk. TG/HDL-C ratio showed stronger association with CHD (37% higher risk in highest quartile) than TyG index. Together, dyslipidemia, diabetes, and hypertension mediated 56% and 47% of the associations for TyG index and TG/HDL-C ratio, respectively.
Confidence Level
High confidence due to large sample size, long follow-up (8.1 years), comprehensive adjustment for confounders, and consistent results across sensitivity analyses. Limitations include non-fasting blood samples and observational design.
Study Flags
Red Flags
- •Non-fasting blood samples used for biomarker calculation
- •Potential healthy volunteer bias in UK Biobank cohort
- •Single baseline measurement limits assessment of changes over time
Surprising Findings
Non-fasting blood samples were used — and the results still held up.
Doctors usually require fasting for lipid and glucose tests because levels fluctuate after eating — yet these ratios predicted heart disease just as well without fasting.
Practical Takeaways
Ask your doctor to calculate your TG/HDL-C ratio from your last lipid panel — if it’s above 3.0, consider lifestyle changes to lower triglycerides and raise HDL.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 572 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Human Cohort Study
Subject
High probability
on the GRADE evidence scale
This study looked at a bunch of people over many years and found that those with higher TyG and TG/HDL numbers tended to get heart problems later. But it didn’t make anyone change their habits — it just watched what happened. So we can say these numbers are linked to heart disease, but we can’t say they cause it.
No conflicts of interest were detected in this study. No score impact.
Strengths
- Very large sample size (n=403,335)
- Long follow-up period (median 8.1 years)
- Comprehensive adjustment for multiple confounders
Weaknesses
- Observational design with no randomization
- Non-fasting blood samples used for glucose and lipid measurements
- Single baseline measurement of exposures, no longitudinal tracking of changes
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Scientists checked two easy-to-calculate numbers from blood tests to see if they could guess who might get heart disease later.
Research results
People with higher numbers had up to 29% more heart disease over 8 years. These numbers were linked to diabetes, high blood pressure, and bad cholesterol, which explained most of the risk.
What this means - more context
Yes — even if someone doesn’t have diabetes or high blood pressure yet, these simple blood markers can signal higher heart disease risk years before symptoms appear.
This study investigates whether the triglyceride-glucose (TyG) index and triglyceride-to-HDL cholesterol (TG/HDL-C) ratio, surrogate markers of insulin resistance, predict cardiovascular disease (CVD) risk in a European population.
In a prospective cohort of 403,335 middle-aged UK Biobank participants followed for 8.1 years, both TyG index and TG/HDL-C ratio were independently associated with increased risk of total CVD and coronary heart disease (CHD), but not stroke, after adjusting for traditional risk factors. The associations were largely mediated by dyslipidemia, type 2 diabetes, and hypertension.
Methods Used
Prospective cohort study using Cox proportional hazards models to analyze incident CVD in 403,335 adults free of CVD at baseline. Biomarkers (TyG index and TG/HDL-C ratio) were calculated from non-fasting blood samples. Mediation analyses assessed contributions of dyslipidemia, type 2 diabetes, and hypertension. Adjustments included age, sex, smoking, BMI, blood pressure, cholesterol, diabetes, and medication use.
Main Finding
Each 1-SD increase in log-transformed TyG index and TG/HDL-C ratio was associated with 8% and 12% higher CVD risk, respectively. Highest vs. lowest quartiles showed 19% and 29% higher CVD risk. TG/HDL-C ratio showed stronger association with CHD (37% higher risk in highest quartile) than TyG index. Together, dyslipidemia, diabetes, and hypertension mediated 56% and 47% of the associations for TyG index and TG/HDL-C ratio, respectively.
Confidence Level
High confidence due to large sample size, long follow-up (8.1 years), comprehensive adjustment for confounders, and consistent results across sensitivity analyses. Limitations include non-fasting blood samples and observational design.
Study Flags
Red Flags
- •Non-fasting blood samples used for biomarker calculation
- •Potential healthy volunteer bias in UK Biobank cohort
- •Single baseline measurement limits assessment of changes over time
Surprising Findings
Non-fasting blood samples were used — and the results still held up.
Doctors usually require fasting for lipid and glucose tests because levels fluctuate after eating — yet these ratios predicted heart disease just as well without fasting.
Practical Takeaways
Ask your doctor to calculate your TG/HDL-C ratio from your last lipid panel — if it’s above 3.0, consider lifestyle changes to lower triglycerides and raise HDL.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 572 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Human Cohort Study
Subject
High probability
on the GRADE evidence scale
This study looked at a bunch of people over many years and found that those with higher TyG and TG/HDL numbers tended to get heart problems later. But it didn’t make anyone change their habits — it just watched what happened. So we can say these numbers are linked to heart disease, but we can’t say they cause it.
No conflicts of interest were detected in this study. No score impact.
Strengths
- Very large sample size (n=403,335)
- Long follow-up period (median 8.1 years)
- Comprehensive adjustment for multiple confounders
Weaknesses
- Observational design with no randomization
- Non-fasting blood samples used for glucose and lipid measurements
- Single baseline measurement of exposures, no longitudinal tracking of changes
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
This study is super well-done because it followed almost half a million people for over 8 years and checked lots of things like age, smoking, and blood pressure to make sure the results weren’t just random. But since it didn’t change anyone’s behavior, we still can’t be 100% sure the numbers themselves are the cause — just strong clues.
75 / 100
- COI disclosure+40/40
- Data availability+35/35
- Code availabilitycode not shared
56 / 100
- Randomizationnot randomized
- Blindingblinding unclear
- Control group+15/15
- Sample size (n=403335)+20/20
- Follow-up+10/10
100 / 100
77 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 572 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. This is an observational cohort study with no randomization or intervention; it can identify associations but cannot rule out confounding factors or establish direct cause-effect relationships.
No Conflicts
No conflicts of interest identified
No conflicts of interest or funding statements were disclosed in the study text. The analysis used publicly available UK Biobank data with no indication of industry involvement or author financial ties.
Independent Analysis Safeguards
- Analysis conducted using UK Biobank's standardized protocols
- Statistical analysis performed with SAS software using publicly available methods
- Multiple imputation for missing data
- Adjustment for multiple confounders in models
- Sensitivity analyses excluding early CVD cases
The study relies entirely on the UK Biobank dataset, which is a publicly funded, open-access resource. No author affiliations, funding sources, or conflict of interest declarations are provided in the text. While this absence prevents confirmation of COI disclosure, the use of a large, independent, population-based cohort with standardized data collection minimizes potential bias.